Skip to main content

Jaguar Health, Inc.

JAGX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001585608

No open-market purchases or sales by Jaguar Health, Inc. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $15.9K in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Jaguar Health, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Jaguar Health, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Jaguar Health, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Micek JohnDirector7,430Mar 12, 20261
Conte Lisa ASee Remarks29,258Jan 21, 20261
King Steven R.See Remarks11,885Jan 21, 20261
Wolin Jonathan S.See Remarks11,938Jan 21, 20261
Bochnowski James JDirector6,415Dec 15, 20251
Siegel Jonathan B.Director7,423Dec 15, 20251
Lizak Carol R.Chief Financial Officer11,911Dec 15, 20251
Jayasuriya AnulaDirector5,916Dec 15, 20251
Chaturvedi Pravin RChief Scientific Officer11,938Dec 15, 20251
Divis Gregory JDirector12,133May 18, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Apr 2, 2025 (view filing)Mar 312 daysMicek JohnDirectorPPurchase+18.0K$50,000.00+$450.0M–9.00K afterDerivative2 lotsPrice outlierDuplicate filing
Apr 2, 2025 (view filing)Mar 312 daysKing Steven R.See RemarksPPurchase+7.20K$20,000.00+$72.0M–3.60K afterDerivative2 lotsPrice outlier
Apr 2, 2025 (view filing)Mar 312 daysSiegel Jonathan B.DirectorPPurchase+18.0K$50,000.00+$450.0M–9.00K afterDerivative2 lotsPrice outlierDuplicate filing
Apr 2, 2025 (view filing)Mar 312 daysConte Lisa ACEO and PresidentPPurchase+18.0K$50,000.00+$450.0M–9.00K afterDerivative2 lotsPrice outlier
Apr 2, 2025 (view filing)Mar 312 daysChaturvedi Pravin RChief Scientific OfficerPPurchase+7.20K$20,000.00+$72.0M–3.60K afterDerivative2 lotsPrice outlier
Apr 2, 2025 (view filing)Mar 312 daysBochnowski James JDirectorPPurchase+54.0K$150,000.00+$4.05B–27.0K afterDerivative2 lotsPrice outlier
Apr 2, 2025 (view filing)Mar 312 daysWolin Jonathan S.See RemarksPPurchase+18.0K$50,000.00+$450.0M–9.00K afterDerivative2 lotsPrice outlier
Apr 2, 2025 (view filing)Mar 312 daysLizak Carol R.Chief Financial OfficerPPurchase+10.8K$30,000.00+$162.0M–5.40K afterDerivative2 lotsPrice outlier
Jan 3, 2023 (view filing)5:03 PM ETDec 31, 20223 daysWolin Jonathan S.Chief of Staff, CCO & GCPPurchase+317$0.03+$9.51+4.8%6.98K after
Mar 30, 2022 (view filing)Sep 13, 2021198 daysLateLizak Carol R.Chief Financial OfficerPPurchase+7.97K$2.51+$20.0KNew position7.97K after
Mar 30, 2022 (view filing)Sep 13, 2021198 daysLateConte Lisa ACEO and PresidentPPurchase+7.97K$2.51+$20.0K+22,765.7%8.00K after